Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 14.08.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ¨ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Offic |
Stammdaten
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
Unternehmen & Branche
| Name | ACTUATE THERAPEUTICS, INC. |
|---|---|
| Ticker | ACTU |
| CIK | 0001652935 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 68,5 Mio. USD |
| Beta | 0,86 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -22,227,852 | -1.06 | 14,035,910 | 7,924,003 | |
| 2025-09-30 | 10-Q | -5,407,470 | -0.25 | 17,713,934 | 10,936,281 | |
| 2025-06-30 | 10-Q | -5,949,405 | -0.30 | 6,968,901 | -2,653,704 | |
| 2025-03-31 | 10-Q | -6,317,024 | -0.32 | 4,483,039 | -5,087,737 | |
| 2024-12-31 | 10-K | -27,285,328 | -3.26 | 9,318,448 | 104,186 | |
| 2024-09-30 | 10-Q | -5,970,961 | -0.55 | 14,262,781 | 5,358,688 | |
| 2024-06-30 | 10-Q | -6,572,219 | -4.20 | 1,730,826 | -114,256,566 | |
| 2024-03-31 | 10-Q | -8,296,059 | -5.40 | -107,774,366 | ||
| 2023-12-31 | 10-K | -24,744,620 | -17.24 | 2,995,566 | -99,626,513 | |
| 2023-09-30 | 10-Q | -6,337,925 | -4.31 | -92,136,409 | ||
| 2023-06-30 | 10-Q | -5,524,286 | -3.88 | -85,953,711 | ||
| 2023-03-31 | 10-Q | -5,270,255 | -80,502,556 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-01-05 | THOMSON TODD S | Director, 10% Owner | Open Market Sale | -280,000 | 5.80 | -1,624,000.00 | -207,9% | |
| 2025-06-27 | Bios Equity COF, LP | Director, 10% Owner | Open Market Purchase | 71,428 | 7.00 | 499,996.00 | +64,0% | |
| 2025-06-27 | Fletcher Aaron G.L. | Director, 10% Owner | Open Market Purchase | 71,428 | 7.00 | 499,996.00 | +64,0% | |
| 2025-06-27 | Kreis Leslie W. | Director, 10% Owner | Open Market Purchase | 71,428 | 7.00 | 499,996.00 | +64,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.